Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hemophilia gene therapy: update.

Paul E Monahan1, Gilbert C White

  • 1Department of Pediatrics, University of North Carolina at Chapel Hill, 418 MacNider Building, CB#7220 UNC-CH, School of Medicine, Chapel Hill, North Carolina 27599-7220, USA. Paul_Monahan@med.unc.edu

Current Opinion in Hematology
|August 13, 2002
PubMed
Summary

Gene transfer shows promise as a safe treatment for hemophilia A and B. Clinical trials indicate current methods are well-tolerated, with ongoing research to enhance efficiency.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to a letter from Miesbach and Srivastava: response to hemophilia B gene therapy based on adeno-associated virus serotype 5 antibody status.

Research and practice in thrombosis and haemostasis·2026
Same author

Etranacogene dezaparvovec in people with hemophilia B with preexisting adeno-associated virus 5 neutralizing antibodies: 4-year subgroup results from the HOPE-B trial.

Research and practice in thrombosis and haemostasis·2026
Same author

Etranacogene dezaparvovec in people with hemophilia B and without adeno-associated virus serotype 5 neutralizing antibodies: a 4-year subgroup analysis of the Health Outcomes with Padua Gene; Evaluation in Hemophilia B (HOPE-B) trial.

Research and practice in thrombosis and haemostasis·2026
Same author

Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B.

The New England journal of medicine·2025
Same author

Natural history of preexisting AAV5 antibodies in adults with hemophilia B during the lead-in of the etranacogene dezaparvovec phase 3 study.

Molecular therapy. Methods & clinical development·2025
Same author

Evaluation of One-Stage Assays for the Monitoring of Recombinant Human Factor IX Padua Activity After Etranacogene Dezaparvovec Gene Therapy.

Haemophilia : the official journal of the World Federation of Hemophilia·2025

Area of Science:

  • Biotechnology
  • Hematology
  • Gene Therapy

Background:

  • Hemophilia A and B are genetic bleeding disorders requiring lifelong treatment.
  • Current treatments for hemophilia involve regular infusions of clotting factors.
  • Gene transfer offers a potential one-time curative approach.

Purpose of the Study:

  • To evaluate the safety and tolerability of gene transfer for hemophilia.
  • To assess the efficacy of gene transfer vectors and dosages in clinical trials.

Main Methods:

  • Phase I clinical trials were conducted to assess safety.
  • Multiple gene transfer vectors and dosages were administered to participants.
  • Adverse events and patient tolerance were closely monitored.

Related Experiment Videos

Main Results:

  • Completed and ongoing Phase I trials demonstrate the safety of gene transfer in hemophilia patients.
  • The gene transfer vectors and dosages utilized were found to be safe and well-tolerated.
  • No significant safety concerns were reported in the conducted trials.

Conclusions:

  • Gene transfer is a safe and well-tolerated therapeutic strategy for hemophilia A and B.
  • Further research is needed to optimize gene transfer efficiency and long-term outcomes.
  • Gene therapy represents a significant advancement in the treatment of hemophilia.